Search
![Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders](https://static.wixstatic.com/media/08e71b_343375df256f40dfa60e93d796a948b4~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_343375df256f40dfa60e93d796a948b4~mv2.png)
- Jun 28
Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders
Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that...